Lowest Price Guaranteed
Slides
240
Last Updated
July 2026
View Count
28672
1. BACKGROUND
1.1. Context
1.2. Project Objectives
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control
3. ECONOMIC AND OTHER PROJECT-SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations
4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product (GDP)
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross-Border Dynamics
4.3. Conclusion
5. EXECUTIVE SUMMARY
6. INTRODUCTION
6.1. Overview of Anti-Obesity Drugs
6.2. Health Risks Linked with Long-term Obesity
6.3. Currently Approved Anti-Obesity Drug Classes
6.4. Challenges Associated with Anti-Obesity Drugs
6.5. Future Perspectives
7. MARKET LANDSCAPE: ANTI-OBESITY DRUGS
7.1. Market Landscape: Anti-Obesity Drugs
7.1.1. Analysis by Status of Development
7.1.2. Analysis by Type of Molecule
7.1.3. Analysis by Mechanism of Action
7.1.4. Analysis by Type of Agonist
7.1.5. Analysis by Route of Administration
7.1.6. Analysis by Dosage Frequency
7.1.7. Analysis by Type of Therapy
7.2. Developer Landscape: Anti-Obesity Drugs
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Company Size
7.2.3. Analysis by Location of Headquarters
7.2.4. Analysis by Headquarters (Country) and Status of Development
7.2.5. Most Active Developers: Analysis by Number of Drug Candidates
8. COMPANY PROFILES: ANTI-OBESITY DRUG DEVELOPERS BASED IN NORTH AMERICA
8.1. Chapter Overview
8.2. Detailed Company Profiles
8.2.1. Eli Lilly
8.2.1.1. Company Details
8.2.1.2. Pipeline Portfolio
8.2.1.3. Financial Details
8.2.1.4. Recent Developments and Future Outlook
8.2.2. Pfizer
8.2.3. Regeneron
8.3. Brief Company Profiles
8.3.1. CinFina Pharma
8.3.1.1. Company Details
8.3.1.2. Pipeline Portfolio
8.3.2. Kallyope
8.3.3. Viking Therapeutics
9. COMPANY PROFILES: ANTI-OBESITY DRUG DEVELOPERS BASED IN EUROPE
9.1. Chapter Overview
9.2. Detailed Company Profiles
9.2.1. AstraZeneca
9.2.1.1. Company Details
9.2.1.2. Pipeline Portfolio
9.2.1.3. Financial Details
9.2.1.4. Recent Developments and Future Outlook
9.2.2. Novo Nordisk
9.2.3. Roche
9.3. Brief Company Profiles
9.3.1. Adocia
9.3.1.1. Company Details
9.3.1.2. Pipeline Portfolio
9.3.2. Boehringer Ingelheim
9.3.3. Zealand Pharma
10. COMPANY PROFILES: ANTI-OBESITY DRUG DEVELOPERS BASED IN ASIA-PACIFIC AND REST OF THE WORLD
10.1. Chapter Overview
10.2. Detailed Company Profiles
10.2.1. Hanmi Pharmaceuticals
10.2.1.1. Company Details
10.2.1.2. Pipeline Portfolio
10.2.1.3. Financial Details
10.2.1.4. Recent Developments and Future Outlook
10.2.2. Jiangsu Hengrui Pharmaceuticals
10.3. Brief Company Profiles
10.3.1. Gmax Biopharma
10.3.1.1. Company Details
10.3.1.2. Pipeline Portfolio
10.3.2. PegBio
10.3.3. QL Biopharm
10.3.4. Sciwind Biosciences
11. BIG PHARMA INITIATIVES
11.1. Methodology
11.2. Big Pharma Players: Anti-obesity focused Initiatives
11.2.1. Analysis of Big Pharma Players by Number of Initiatives
11.2.2. Analysis by Year of Initiative
11.2.3. Analysis by Big Pharma Player by Year of Initiative and Number of Initiatives
11.2.4. Analysis by Type of Initiative
11.2.5. Analysis by Year and Type of Initiative
11.2.6. Analysis by Big Pharma Player and Type of Initiative
11.2.7. Analysis by Big Pharma Player and Number of Partnerships
11.2.8. Analysis by Type of Partnership
11.2.9. Analysis by Type of Expansion
11.2.10. Analysis by Big Pharma Player by Region and Number of Initiatives
11.2.11. Benchmarking of Big Pharma Players
12. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
12.1. Chapter Overview
12.2. Market Drivers
12.3. Market Restraints
12.4. Market Opportunities
12.5. Market Challenges
13. GLOBAL ANTI-OBESITY DRUGS MARKET
13.1. Forecast Methodology and Key Assumptions
13.2. Global Anti-Obesity Drugs Market, Historical Trends (Since 2019) and Forecasted Estimates (Till 2035) (USD Billion)
13.2.1. Scenario Analysis
13.2.1.1. Conservative Scenario
13.2.1.2. Optimistic Scenario
13.3. Key Market Segmentations
14. ANTI-OBESITY DRUGS MARKET, BY TYPE OF MOLECULE
14.1. Anti-Obesity Drugs Market: Distribution by Type of Molecule
14.1.1. Anti-Obesity Drugs Market for Biologics, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
14.1.2. Anti-Obesity Drugs Market for Small Molecules, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
15. ANTI-OBESITY DRUGS MARKET, BY TYPE OF DRUG
15.1. Anti-Obesity Drugs Market: Distribution by Type of Drug
15.1.1. Anti-Obesity Drugs Market for Prescription Drugs, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
15.1.2. Anti-Obesity Drugs Market for OTC Drugs, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
16. ANTI-OBESITY DRUGS MARKET, BY ACTIVE COMPOUND USED
16.1. Anti-Obesity Drugs Market: Distribution by Active Compound Used
16.1.1. Anti-Obesity Drugs Market for Tirzepatide, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
16.1.2. Anti-Obesity Drugs Market for Semaglutide, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
16.1.3. Anti-Obesity Drugs Market for Retatrutide, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
16.1.4. Anti-Obesity Drugs Market for Survodutide, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
16.1.5. Anti-Obesity Drugs Market for Cagrilintide and Semaglutide, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
16.1.6. Anti-Obesity Drugs Market for Orforglipron, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
16.1.7. Anti-Obesity Drugs Market for Liraglutide, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
16.1.8. Anti-Obesity Drugs Market for other active compounds used, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
17. ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION
17.1. Anti-Obesity Drugs Market: Distribution by Mechanism of Action
17.1.1. Anti-Obesity Drugs Market for GLP-1 Agonist / GIP Agonist, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
17.1.2. Anti-Obesity Drugs Market for GLP-1 Agonist, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
17.1.3. Anti-Obesity Drugs Market for GLP-1 Agonist / GCGR Agonist, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
17.1.4. Anti-Obesity Drugs Market for GLP-1 / GCGR / GIP Agonist, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
17.1.5. Anti-Obesity Drugs Market for GLP-1 Agonist / Amylin Analogue, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
17.1.6. Anti-Obesity Drugs Market for Other Mechanisms of Action, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
18. ANTI-OBESITY DRUGS MARKET, BY TYPE OF AGONIST
18.1. Anti-Obesity Drugs Market: Distribution by Type of Agonist
18.1.1. Anti-Obesity Drugs Market for Single-Agonist, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
18.1.2. Anti-Obesity Drugs Market for Dual-Agonist, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
18.1.3. Anti-Obesity Drugs Market for Tri-Agonist, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
19. ANTI-OBESITY DRUGS MARKET, BY ACTION PATHWAY
19.1. Anti-Obesity Drugs Market: Distribution by Action Pathway
19.1.1. Anti-Obesity Drugs Market for Centrally Acting Drugs, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
19.1.2. Anti-Obesity Drugs Market for Peripherally Acting Drugs, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
19.1.3. Anti-Obesity Drugs Market for Centrally Acting and Peripherally Acting Drugs, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
20. ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION
20.1. Anti-Obesity Drugs Market: Distribution by Route of Administration
20.1.1. Anti-Obesity Drugs Market for Oral Administration, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
20.1.2. Anti-Obesity Drugs Market for Parenteral Administration, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
21. ANTI-OBESITY DRUGS MARKET, BY DISTRIBUTION CHANNEL
21.1. Anti-Obesity Drugs Market: Distribution by Distribution Channel
21.1.1. Anti-Obesity Drugs Market for Hospital Pharmacy, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
21.1.2. Anti-Obesity Drugs Market for Retail and Online Pharmacy, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
22. ANTI-OBESITY DRUGS MARKET, BY KEY GEOGRAPHICAL REGIONS
22.1. Anti-Obesity Drugs Market: Distribution by Key Geographical Regions
22.1.1. Anti-Obesity Drugs Market in North America, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
22.1.2. Anti-Obesity Drugs Market in Europe, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
22.1.3. Anti-Obesity Drugs Market in Asia-Pacific, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
22.1.4. Anti-Obesity Drugs Market in Latin America, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
23. ANTI-OBESITY DRUGS MARKET, SALES FORECAST OF MARKETED AND PHASE III DRUGS
23.1. Marketed Drugs: Sales Forecast
23.1.1. Contrave / Mysimba (Naltrexone, Bupropion)
23.1.2. Feisumei (Beinaglutide)
23.1.3. Imcivree (Setmelanotide)
23.1.4. LOMAIRA (Phentermine Hydrochloride)
23.1.5. QSYMIA (Phentermine and Topiramate)
23.1.6. Saxenda (Liraglutide)
23.1.7. Wegovy / Ozempic (Semaglutide)
23.1.8. Zepbound / Mounjaro (Tirzepatide)
23.2. Phase III Drugs: Sales Forecast
23.2.1. BI 456906 (Survodutide)
23.2.2. CagriSema (Cagrilintide and Semaglutide)
23.2.3. HM11260C (Efpeglenatide)
23.2.4. HRS-9531
23.2.5. IBI362 (Mazdutide)
23.2.6. LM-008
23.2.7. LY3437943 (Retatrutide)
23.2.8. LY3502970 (Orforglipron)
23.2.9. TG103
23.2.10. Semaglutide 7.2 mg (Subcutaneous)
23.2.11. Semaglutide (Oral)
23.2.12. XW003
24. ANTI-OBESITY DRUGS MARKET, BY KEY PLAYERS
25. EXECUTIVE INSIGHTS
25.1. Chapter Overview
25.2. Company A
25.2.1. Company Snapshot
25.2.2. Interview Transcript: Co-founder and Chief Medical Advisor
25.3. Company B
25.3.1. Company Snapshot
25.3.2. Interview Transcript: Chief Executive Officer
25.4. Company C
25.4.1. Company Snapshot
25.4.2. Interview Transcript: Chief Executive Officer
25.5. Company D
25.5.1. Company Snapshot
25.5.2. Interview Transcript: Chief Physician Editor, Health and Lifestyle Medicine
25.6. Company E
25.6.1. Company Snapshot
25.6.2. Interview Transcript: Endocrinologist and Owner
25.7. Company F
25.7.1. Company Snapshot
25.7.2. Interview Transcript: Associate Professor of Medicine and Pediatrics
25.8. Company G
25.8.1. Company Snapshot
25.8.2. Interview Transcript: Professor of Medicine Division of Diabetes
25.9. Company H
25.9.1. Company Snapshot
25.9.2. Interview Transcript: Research Scientist
25.10. Company I
25.10.1. Company Snapshot
25.10.2. Interview Transcript: Former Chief Executive Officer
25.11. Company J
25.11.1. Company Snapshot
25.11.2. Interview Transcript: Former Vice President of IDEA
26. APPENDIX 1: TABULATED DATA
27. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Data Sources for Secondary Research
Figure 2.3 Research Methodology: Robust Quality Control
Figure 3.1 Market Dynamics: Forecast Methodology
Figure 3.2 Market Dynamics: Market Assessment Framework
Figure 4.1 Lessons Learnt from Past Recessions
Figure 6.1 Health Risks Linked with Long-term Obesity
Figure 6.2 Currently Approved Anti-Obesity Drug Classes
Figure 7.1 Anti-Obesity Drugs: Distribution by Status of Development
Figure 7.2 Anti-Obesity Drugs: Distribution by Type of Molecule
Figure 7.3 Anti-Obesity Drugs: Distribution by Mechanism of Action
Figure 7.4 Anti-Obesity Drugs: Distribution by Type of Agonist
Figure 7.5 Anti-Obesity Drugs: Distribution by Route of Administration
Figure 7.6 Anti-Obesity Drugs: Distribution by Dosage Frequency
Figure 7.7 Anti-Obesity Drugs: Distribution by Type of Therapy
Figure 7.8 Anti-Obesity Drug Developers: Distribution by Year of Establishment
Figure 7.9 Anti-Obesity Drug Developers: Distribution by Company Size
Figure 7.10 Anti-Obesity Drug Developers: Distribution by Location of Headquarters
Figure 7.11 Anti-Obesity Drug Developers: Distribution by Headquarters (Country) and Status of Development
Figure 7.12 Most Active Developers: Distribution by Number of Drug Candidates
Figure 8.1 Eli Lilly: Annual Revenues (USD Billion)
Figure 8.2 Pfizer: Annual Revenues (USD Billion)
Figure 8.3 Regeneron: Annual Revenues (USD Billion)
Figure 9.1 AstraZeneca: Annual Revenues (USD Billion)
Figure 9.2 Novo Nordisk: Annual Revenues (DKK Billion)
Figure 9.3 Roche: Annual Revenues (CHF Billion)
Figure 10.1 Hanmi Pharmaceuticals: Annual Revenues (KRW Billion)
Figure 10.2 Jiangsu Hengrui Pharmaceuticals: Annual Revenues (CNY Billion)
Figure 11.1 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Initiatives
Figure 11.2 Big Pharma Initiatives: Distribution by Year of Initiative
Figure 11.3 Big Pharma Initiatives: Distribution by Big Pharma Players by Year and Number of Initiatives
Figure 11.4 Big Pharma Initiatives: Distribution by Type of Initiative
Figure 11.5 Big Pharma Initiatives: Distribution by Year and Type of Initiative
Figure 11.6 Big Pharma Initiatives: Distribution by Big Pharma Players and Type of Initiative
Figure 11.7 Big Pharma Initiatives: Distribution by Type of Partnership
Figure 11.8 Big Pharma Initiatives: Distribution by Type of Expansion
Figure 11.9 Big Pharma Initiatives: Distribution of Big Pharma Players by Region and Number of Initiatives
Figure 11.10 Benchmarking of Big Pharma Players
Figure 12.1 Anti-Obesity Drugs: Market Drivers
Figure 12.2 Anti-Obesity Drugs: Market Restraints
Figure 12.3 Anti-Obesity Drugs: Market Opportunities
Figure 12.4 Anti-Obesity Drugs: Market Challenges
Figure 13.1 Global Anti-Obesity Drugs Market, Historical Trends (Since 2019) and Forecasted Estimates (till 2035)
Figure 13.2 Global Anti-obesity Drugs Market, till 2035 (USD Billion): Conservative Scenario
Figure 13.3 Global Anti-obesity Drugs Market, till 2035 (USD Billion): Optimistic Scenario
Figure 14.1 Anti-obesity Drugs Market: Distribution by Type of Molecule
Figure 14.2 Anti-obesity Market for Biologics, till 2035 (USD Billion)
Figure 14.3 Anti-obesity Market for Small Molecules, till 2035 (USD Billion)
Figure 15.1 Anti-obesity Drugs Market: Distribution by Type of Drug
Figure 15.2 Anti-obesity Market for Prescription Drugs, till 2035 (USD Billion)
Figure 15.3 Anti-obesity Market for OTC Drugs, till 2035 (USD Billion)
Figure 16.1 Anti-obesity Drugs Market: Distribution by Active Compound Used
Figure 16.2 Anti-obesity Market for Tirzepatide, till 2035 (USD Billion)
Figure 16.3 Anti-obesity Market for Semaglutide, till 2035 (USD Billion)
Figure 16.4 Anti-obesity Market for Retatrutide, till 2035 (USD Billion)
Figure 16.5 Anti-obesity Market for Survodutide, till 2035 (USD Billion)
Figure 16.6 Anti-obesity Market for Cagrilintide / Semaglutide, till 2035 (USD Billion)
Figure 16.7 Anti-obesity Market for Orforglipron, till 2035 (USD Billion)
Figure 16.8 Anti-obesity Market for Liraglutide, till 2035 (USD Billion)
Figure 16.9 Anti-obesity Market for Other Compounds, till 2035 (USD Billion)
Figure 17.1 Anti-obesity Drugs Market: Distribution by Mechanism of Action
Figure 17.2 Anti-obesity Market for GLP-1 Agonist / GIP Agonist, till 2035 (USD Billion)
Figure 17.3 Anti-obesity Market for GLP-1 Agonist, till 2035 (USD Billion)
Figure 17.4 Anti-obesity Market for GLP-1 Agonist / GCGR Agonist, till 2035 (USD Billion)
Figure 17.5 Anti-obesity Market for GLP-1 / GCGR / GIP Agonist, till 2035 (USD Billion)
Figure 17.6 Anti-obesity Market for GLP-1 Agonist / Amylin Analogue, till 2035 (USD Billion)
Figure 17.7 Anti-obesity Market for Other Mechanisms of Action, till 2035 (USD Billion)
Figure 18.1 Anti-obesity Market: Distribution by Type of Agonist
Figure 18.2 Anti-obesity Market for Single-Agonist, till 2035 (USD Billion)
Figure 18.3 Anti-obesity Market for Dual-Agonist, till 2035 (USD Billion)
Figure 18.4 Anti-obesity Market for Tri-Agonist, till 2035 (USD Billion)
Figure 19.1 Anti-obesity Drugs Market: Distribution by Action Pathway
Figure 19.2 Anti-obesity Market for Centrally Acting Drugs, till 2035 (USD Billion)
Figure 19.3 Anti-obesity Market for Peripherally Acting Drugs, till 2035 (USD Billion)
Figure 19.4 Anti-obesity Market for Centrally and Peripherally Acting Drugs, till 2035 (USD Billion)
Figure 20.1 Anti-obesity Drugs Market: Distribution by Route of Administration
Figure 20.2 Anti-obesity Market for Oral Administration, till 2035 (USD Billion)
Figure 20.3 Anti-obesity Market for Parenteral Administration, till 2035 (USD Billion)
Figure 21.1 Anti-obesity Drugs Market: Distribution by Distribution Channel
Figure 21.2 Anti-obesity Market for Hospital Pharmacy, till 2035 (USD Billion)
Figure 21.3 Anti-obesity Market for Retail and Online Pharmacy, till 2035 (USD Billion)
Figure 22.1 Anti-obesity Drugs Market: Distribution by Key Geographical Regions
Figure 22.2 Anti-obesity Market in North America, till 2035 (USD Billion)
Figure 22.3 Anti-obesity Market in North America (country-wise), till 2035 (USD Billion)
Figure 22.4 Anti-obesity Market in Europe, till 2035 (USD Billion)
Figure 22.5 Anti-obesity Market in Europe (country-wise), till 2035 (USD Billion)
Figure 22.6 Anti-obesity Market in Asia-Pacific, till 2035 (USD Billion)
Figure 22.7 Anti-obesity Market in Asia-Pacific (country-wise), till 2035 (USD Billion)
Figure 22.8 Anti-obesity Market in Latin America, till 2035 (USD Billion)
Figure 22.9 Anti-obesity Market in Latin America (country-wise), till 2035 (USD Billion)
Figure 23.1 Contrave / Mysimba (Naltrexone, Bupropion) Sales Forecast, till 2035 (USD Billion)
Figure 23.2 Feisumei (Beinaglutide) Sales Forecast, till 2035 (USD Billion)
Figure 23.3 Imcivree (Setmelanotide) Sales Forecast, till 2035 (USD Billion)
Figure 23.4 LOMAIRA (Phentermine Hydrochloride) Sales Forecast, till 2035 (USD Billion)
Figure 23.5 QSYMIA (Phentermine and Topiramate) Sales Forecast, till 2035 (USD Billion)
Figure 23.6 Saxenda (Liraglutide) Sales Forecast, till 2035 (USD Billion)
Figure 23.7 Wegovy / Ozempic (Semaglutide) Sales Forecast, till 2035 (USD Billion)
Figure 23.8 Zepbound / Mounjaro (Tirzepatide) Sales Forecast, till 2035 (USD Billion)
Figure 23.9 BI 456906 (Survodutide) Sales Forecast, till 2035 (USD Billion)
Figure 23.10 CagriSema (Cagrilintide and Semaglutide) Sales Forecast, till 2035 (USD Billion)
Figure 23.11 HM11260C (Efpeglenatide) Sales Forecast, till 2035 (USD Billion)
Figure 23.12 HRS-9531 Sales Forecast, till 2035 (USD Billion)
Figure 23.13 IBI362 (Mazdutide) Sales Forecast, till 2035 (USD Billion)
Figure 23.14 LM-008 Sales Forecast, till 2035 (USD Billion)
Figure 23.15 LY3437943 (Retatrutide) Sales Forecast, till 2035 (USD Billion)
Figure 23.16 LY3502970 (Orforglipron) Sales Forecast, till 2035 (USD Billion)
Figure 23.17 TG103 Sales Forecast, till 2035 (USD Billion)
Figure 23.18 Semaglutide 7.2 mg (Subcutaneous) Sales Forecast, till 2035 (USD Billion)
Figure 23.19 Semaglutide (Oral) Sales Forecast, till 2035 (USD Billion)
Figure 23.20 XW003 Sales Forecast, till 2035 (USD Billion)
Figure 24.1 Anti-obesity Drugs Market: Distribution by Key Players, 2020 (USD Billion)
Figure 24.2 Anti-obesity Drugs Market: Distribution by Key Players, Current Year (USD Billion)
Figure 24.3 Anti-obesity Drugs Market: Distribution by Key Players, 2035 (USD Billion)
Table 7.1 List of Anti-Obesity Drugs
Table 7.2 List of Anti-Obesity Drug Developers
Table 8.1 Eli Lily: Pipeline Portfolio
Table 8.2 Eli Lily: Recent Developments and Future Outlook
Table 8.3 Pfizer: Pipeline Portfolio
Table 8.4 Pfizer: Recent Developments and Future Outlook
Table 8.5 Regeneron: Pipeline Portfolio
Table 8.6 Regeneron: Recent Developments and Future Outlook
Table 8.7 CinFina Pharma: Pipeline Portfolio
Table 8.8 Kallyope: Pipeline Portfolio
Table 8.9 Viking Therapeutics: Pipeline Portfolio
Table 9.1 AstraZeneca: Pipeline Portfolio
Table 9.2 AstraZeneca: Recent Developments and Future Outlook
Table 9.3 Novo Nordisk: Pipeline Portfolio
Table 9.4 Novo Nordisk: Recent Developments and Future Outlook
Table 9.5 Roche: Pipeline Portfolio
Table 9.6 Roche: Recent Developments and Future Outlook
Table 9.7 Adocia: Pipeline Portfolio
Table 9.8 Boehringer Ingelheim: Pipeline Portfolio
Table 9.9 Zealand Pharma: Pipeline Portfolio
Table 10.1 Hanmi Pharmaceuticals: Pipeline Portfolio
Table 10.2 Hanmi Pharmaceuticals: Recent Developments and Future Outlook
Table 10.3 Jiangsu Hengrui Pharmaceuticals: Pipeline Portfolio
Table 10.4 Jiangsu Hengrui Pharmaceuticals: Recent Developments and Future Outlook
Table 10.5 Gmax Biopharma: Pipeline Portfolio
Table 10.6 PegBio: Pipeline Portfolio
Table 10.7 QL Biopharm: Pipeline Portfolio
Table 10.8 Sciwind Biosciences: Pipeline Portfolio
Table 11.1 Big Pharma Players: List of Anti-obesity Focused Initiatives
Table 13.1 Anti-obesity Market: List of Forecasted Drugs
Table 26.1 Anti-Obesity Drugs: Distribution by Status of Development
Table 26.2 Anti-Obesity Drugs: Distribution by Type of Molecule
Table 26.3 Anti-Obesity Drugs: Distribution by Mechanism of Action
Table 26.4 Anti-Obesity Drugs: Distribution by Type of Agonist
Table 26.5 Anti-Obesity Drugs: Distribution by Route of Administration
Table 26.6 Anti-Obesity Drugs: Distribution by Dosage Frequency
Table 26.7 Anti-Obesity Drugs: Distribution by Type of Therapy
Table 26.8 Anti-Obesity Drug Developers: Distribution by Year of Establishment
Table 26.9 Anti-Obesity Drug Developers: Distribution by Company Size
Table 26.10 Anti-Obesity Drug Developers: Distribution by Location of Headquarters
Table 26.11 Anti-Obesity Drug Developers: Distribution by Headquarters (Country) and Status of Development
Table 26.12 Most Active Developers: Distribution by Number of Drugs
Table 26.13 Eli Lilly: Annual Revenues (USD Billion)
Table 26.14 Pfizer: Annual Revenues (USD Billion)
Table 26.15 Regeneron: Annual Revenues (USD Billion)
Table 26.16 AstraZeneca: Annual Revenues (USD Billion)
Table 26.17 Novo Nordisk: Annual Revenues (DKK Billion)
Table 26.18 Roche: Annual Revenues (CHF Billion)
Table 26.19 Hanmi Pharmaceuticals: Annual Revenues (KRW Billion)
Table 26.20 Jiangsu Hengrui Pharmaceuticals: Annual Revenues (CNY Billion)
Table 26.21 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Initiatives
Table 26.22 Big Pharma Initiatives: Distribution by Year of Initiative
Table 26.23 Big Pharma Initiatives: Distribution by Big Pharma Players by Year and Number of Initiatives
Table 26.24 Big Pharma Initiatives: Distribution by Type of Initiative
Table 26.25 Big Pharma Initiatives: Distribution by Year and Type of Initiative
Table 26.26 Big Pharma Initiatives: Distribution by Big Pharma Players and Type of Initiative
Table 26.27 Big Pharma Initiatives: Distribution by Type of Partnership
Table 26.28 Big Pharma Initiatives: Distribution by Type of Expansion
Table 26.29 Big Pharma Initiatives: Distribution by Big Pharma Players by Region and Number of Initiatives
Table 26.30 Global Anti-Obesity Drugs Market, Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
Table 26.31 Global Anti-obesity Drugs Market, till 2035 (USD Billion): Conservative Scenario
Table 26.32 Global Anti-obesity Drugs Market, till 2035 (USD Billion): Optimistic Scenario
Table 26.33 Anti-obesity Drugs Market: Distribution by Type of Molecule
Table 26.34 Anti-obesity Market for Biologics, till 2035 (USD Billion)
Table 26.35 Anti-obesity Market for Small Molecules, till 2035 (USD Billion)
Table 26.36 Anti-obesity Drugs Market: Distribution by Type of Drug
Table 26.37 Anti-obesity Market for Prescription Drugs, till 2035 (USD Billion)
Table 26.38 Anti-obesity Market for OTC Drugs, till 2035 (USD Billion)
Table 26.39 Anti-obesity Drugs Market: Distribution by Active Compound Used
Table 26.40 Anti-obesity Market for Tirzepatide, till 2035 (USD Billion)
Table 26.41 Anti-obesity Market for Semaglutide, till 2035 (USD Billion)
Table 26.42 Anti-obesity Market for Retatrutide, till 2035 (USD Billion)
Table 26.43 Anti-obesity Market for Survodutide, till 2035 (USD Billion)
Table 26.44 Anti-obesity Market for Cagrilintide / Semaglutide, till 2035 (USD Billion)
Table 26.45 Anti-obesity Market for Orforglipron, till 2035 (USD Billion)
Table 26.46 Anti-obesity Market for Liraglutide, till 2035 (USD Billion)
Table 26.47 Anti-obesity Market for Other Compounds, till 2035 (USD Billion)
Table 26.48 Anti-obesity Drugs Market: Distribution by Mechanism of Action
Table 26.49 Anti-obesity Market for GLP-1 Agonist / GIP Agonist, till 2035 (USD Billion)
Table 26.50 Anti-obesity Market for GLP-1 Agonist, till 2035 (USD Billion)
Table 26.51 Anti-obesity Market for GLP-1 / GCGR / GIP Agonist, till 2035 (USD Billion)
Table 26.52 Anti-obesity Market for GLP-1 Agonist / GCGR Agonist, till 2035 (USD Billion)
Table 26.53 Anti-obesity Market for GLP-1 Agonist / Amylin Analogue, till 2035 (USD Billion)
Table 26.54 Anti-obesity Market for Other Mechanisms of Action, till 2035 (USD Billion)
Table 26.55 Anti-obesity Market: Distribution by Type of Agonist
Table 26.56 Anti-obesity Market for Single-Agonist, till 2035 (USD Billion)
Table 26.57 Anti-obesity Market for Dual-Agonist, till 2035 (USD Billion)
Table 26.58 Anti-obesity Market for Tri-Agonist, till 2035 (USD Billion)
Table 26.59 Anti-obesity Drugs Market: Distribution by Action Pathway
Table 26.60 Anti-obesity Market for Centrally Acting Drugs, till 2035 (USD Billion)
Table 26.61 Anti-obesity Market for Peripherally Acting Drugs, till 2035 (USD Billion)
Table 26.62 Anti-obesity Market for Centrally and Peripherally Acting, till 2035 (USD Billion)
Table 26.63 Anti-obesity Drugs Market: Distribution by Route of Administration
Table 26.64 Anti-obesity Market for Parenteral Administration, till 2035 (USD Billion)
Table 26.65 Anti-obesity Market for Oral Administration, till 2035 (USD Billion)
Table 26.66 Anti-obesity Drugs Market: Distribution by Distribution Channel
Table 26.67 Anti-obesity Market for Hospital Pharmacy, till 2035 (USD Billion)
Table 26.68 Anti-obesity Market for Retail and Online Pharmacy, till 2035 (USD Billion)
Table 26.69 Anti-obesity Drugs Market: Distribution by Geography
Table 26.70 Anti-obesity Market in North America, till 2035 (USD Billion)
Table 26.71 Anti-obesity Market in North America (country-wise), till 2035 (USD Billion)
Table 26.72 Anti-obesity Market in Europe, till 2035 (USD Billion)
Table 26.73 Anti-obesity Market in Europe (country-wise), till 2035 (USD Billion)
Table 26.74 Anti-obesity Market in Asia-Pacific, till 2035 (USD Billion)
Table 26.75 Anti-obesity Market in Asia-Pacific (country-wise), till 2035 (USD Billion)
Table 26.76 Anti-obesity Market in Latin America, till 2035 (USD Billion)
Table 26.77 Anti-obesity Market in Latin America (country-wise), till 2035 (USD Billion)
Table 26.78 Contrave / Mysimba (Naltrexone, Bupropion) Sales Forecast, till 2035 (USD Billion)
Table 26.79 Feisumei (Beinaglutide) Sales Forecast, till 2035 (USD Billion)
Table 26.80 Imcivree (Setmelanotide) Sales Forecast, till 2035 (USD Billion)
Table 26.81 LOMAIRA (Phentermine Hydrochloride) Sales Forecast, till 2035 (USD Billion)
Table 26.82 QSYMIA (Phentermine and Topiramate) Sales Forecast, till 2035 (USD Billion)
Table 26.83 Saxenda (Liraglutide) Sales Forecast, till 2035 (USD Billion)
Table 26.84 Wegovy / Ozempic (Semaglutide) Sales Forecast, till 2035 (USD Billion)
Table 26.85 Zepbound / Mounjaro (Tirzepatide) Sales Forecast, till 2035 (USD Billion)
Table 26.86 BI 456906 (Survodutide) Sales Forecast, till 2035 (USD Billion)
Table 26.87 CagriSema (Cagrilintide and Semaglutide) Sales Forecast, till 2035 (USD Billion)
Table 26.88 HM11260C (Efpeglenatide) Sales Forecast, till 2035 (USD Billion)
Table 26.89 HRS-9531 Sales Forecast, till 2035 (USD Billion)
Table 26.90 IBI362 (Mazdutide) Sales Forecast, till 2035 (USD Billion)
Table 26.91 LM-008 Sales Forecast, till 2035 (USD Billion)
Table 26.92 LY3437943 (Retatrutide) Sales Forecast, till 2035 (USD Billion)
Table 26.93 LY3502970 (Orforglipron) Sales Forecast, till 2035 (USD Billion)
Table 26.94 TG103 Sales Forecast, till 2035 (USD Billion)
Table 26.95 Semaglutide 7.2 mg (Subcutaneous) Sales Forecast, till 2035 (USD Billion)
Table 26.96 Semaglutide (Oral) Sales Forecast, till 2035 (USD Billion)
Table 26.97 XW003 Sales Forecast, till 2035 (USD Billion)
Table 26.98 Anti-obesity Drugs Market: Distribution by Key Players, 2020 (USD Billion)
Table 26.99 Anti-obesity Drugs Market: Distribution by Key Players, Current Year (USD Billion)
Table 26.100 Anti-obesity Drugs Market: Distribution by Key Players, 2035 (USD Billion)